ATNM-400

ATNM-400 is a novel, first-in-class antibody radioconjugate developed by Actinium Pharmaceuticals, Inc. It utilizes Actinium-225 (Ac-225), an alpha-emitter radioisotope, conjugated to an antibody via p-SCN-Bn-DOTA. The drug targets an unspecified protein that is associated with poor prognosis, is overexpressed in various cancers including non-small cell lung cancer (NSCLC), prostate cancer, and breast cancer, and is linked to increased metastasis and resistance to treatments like EGFR tyrosine kinase inhibitors (TKIs). ATNM-400 is designed to deliver potent alpha-particle radiation directly to cancer cells, inducing irreparable double-strand DNA breaks, thereby overcoming resistance to existing therapies such as Osimertinib in NSCLC and androgen receptor pathway inhibitors (ARPIs) and PSMA-targeted radiotherapies in prostate cancer. It has demonstrated strong anti-tumor efficacy and favorable tolerability in preclinical models across multiple cancer subtypes.

Other names

177Lu-HER3-ARC225Ac-HER3-ARCAc-225 barecetamab-DOTAAc225 barecetamab-DOTAAc 225 barecetamab-DOTAHER3 ARCHER-3 ARCHER 3 ARCHER3-ARCHER-3-ARCHER 3-ARCZr-89 barecetamab-DFOZr89 barecetamab-DFOZr 89 barecetamab-DFO[225Ac]-barecetamab-DOTA[89Zr]-barecetamab-DFO